CN118059315A - Method for removing residual glutaraldehyde based on indirect centrifugation - Google Patents
Method for removing residual glutaraldehyde based on indirect centrifugation Download PDFInfo
- Publication number
- CN118059315A CN118059315A CN202410405439.6A CN202410405439A CN118059315A CN 118059315 A CN118059315 A CN 118059315A CN 202410405439 A CN202410405439 A CN 202410405439A CN 118059315 A CN118059315 A CN 118059315A
- Authority
- CN
- China
- Prior art keywords
- glutaraldehyde
- centrifugation
- biological material
- filter cloth
- indirect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 238000000034 method Methods 0.000 title claims abstract description 47
- 238000005119 centrifugation Methods 0.000 title claims abstract description 40
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 100
- 239000012620 biological material Substances 0.000 claims abstract description 53
- 239000004471 Glycine Substances 0.000 claims abstract description 50
- 239000004744 fabric Substances 0.000 claims abstract description 21
- 238000006386 neutralization reaction Methods 0.000 claims abstract description 12
- 238000007789 sealing Methods 0.000 claims abstract description 4
- 238000002791 soaking Methods 0.000 claims description 26
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 18
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 18
- 210000002744 extracellular matrix Anatomy 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 9
- 239000000515 collagen sponge Substances 0.000 claims description 7
- 108010022355 Fibroins Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 26
- 230000003472 neutralizing effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 32
- 210000004303 peritoneum Anatomy 0.000 description 10
- 238000002386 leaching Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- -1 amino, carboxyl Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000005238 degreasing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004383 yellowing Methods 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 108010020199 glutaraldehyde-cross-linked collagen Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the field of biomedical materials, and particularly relates to a method for removing residual glutaraldehyde based on indirect centrifugation. The method comprises the following specific steps: 1) Neutralizing biological material containing glutaraldehyde in glycine solution; 2) Placing the biological material subjected to neutralization treatment into filter cloth, sealing the filter cloth, fixing the filter cloth in the middle of a centrifuge tube, and centrifugally removing glutaraldehyde in an indirect centrifugal manner; 3) Centrifugation was repeated 1 time.
Description
Filing and applying for separate cases
The application is based on the application number CN202311244739.2, the application day 2023, 9 and 25, and the application name is a divisional application of Chinese patent application of 'a method for removing residual glutaraldehyde in glutaraldehyde crosslinked biological materials'.
Technical Field
The invention belongs to the field of biomedical materials, and particularly relates to a method for removing residual glutaraldehyde based on indirect centrifugation.
Background
Biological materials refer to a class of materials that can be used to diagnose, treat, repair, or replace diseased tissues, organs, or enhance the function of an organism, and can be further subdivided into synthetic biological materials and natural biological materials. For some common natural macromolecular biological materials, such as collagen, cellulose, chitosan, gelatin, silk fibroin, extracellular matrix and the like, the surface of the natural macromolecular biological materials is usually provided with abundant hydroxyl, amino, carboxyl and other characteristic groups, so that a plurality of chemical reaction sites are provided for the materials, and the possibility is provided for the realization of the functionalization and high performance of the materials. However, after the natural biological macromolecular materials are further regenerated or processed, the mechanical properties of the obtained subsequent materials often cannot meet the application requirements, so that the mechanical properties of the materials are required to be further improved by physical crosslinking or chemical crosslinking means, and the high performance is realized.
Glutaraldehyde is one of the crosslinking agents currently considered to have the best crosslinking strength, however, since glutaraldehyde (including free glutaraldehyde molecules and glutaraldehyde residues) remained in the glutaraldehyde-treated biomaterial has strong cytotoxicity, thus limiting the deep application in the biomaterial field. At present, the method for removing residual glutaraldehyde in glutaraldehyde crosslinking biological materials mainly comprises the following 3 steps: (1) Repeated washing, such as washing with glycine, but this method can only remove glutaraldehyde crosslinked on the surface of the material, and has limited removal effect on residual glutaraldehyde penetrating into the interior of the material. (2) Heat treatment, such as a heat treatment at a high temperature of 120 c for 12 hours, removes glutaraldehyde from the crosslinked collagen, but this process, if improperly controlled, may cause high temperature denaturation of the collagen. (3) The supercritical carbon dioxide is used for extracting residual glutaraldehyde, but the equipment cost for constructing a supercritical carbon dioxide platform is higher, the extraction and removal process has higher difficulty, and the high-pressure condition also provides higher requirements on safety. Therefore, a low-cost, simple and efficient glutaraldehyde removal method is sought, and has great promotion effect on promoting the wide clinical application of biological materials to tissue repair and regeneration.
The patent with the application number of CN202210860705.5, the name of the treatment process of biological tissue sheet and the biological tissue sheet obtained by the process, discloses a method for cleaning the biological tissue sheet which is firstly crosslinked and fixed by glutaraldehyde by NaCl aqueous solution for 1-8 times, and then mixing and reacting with glycine solution for 3-6 hours to remove residual glutaraldehyde. However, the action of glycine in this method is to neutralize glutaraldehyde as a chemical neutralizing agent, but glutaraldehyde after the neutralization remains in the inside of the biological tissue sheet per se and thus the problem of removing glutaraldehyde from the biological tissue sheet is not really solved. Therefore, the biological tissue slice treated by the method still has a certain glutaraldehyde residue, so that the biological tissue slice still has lower biotoxicity. In addition, studies have shown that the product of the reaction of glycine and glutaraldehyde is glycyl glutaraldehyde, which can cause yellowing of the treated biological material. And glycyl glutaraldehyde is unstable and is easily decomposed into glycine and glutaraldehyde again. On the other hand, glycine remaining in the biological material will oxidize and turn the material yellow. Therefore, the removal of the reaction products and residues of glycine and glutaraldehyde is particularly important. Finally, the process of the patent method takes a long time, and only soaking with glycine takes 3-6 hours.
In view of the foregoing, there is a need for improved methods and strategies to effectively remove residual glutaraldehyde from biological materials, improving the safety and applicability of biological materials.
Disclosure of Invention
In view of the above, the present invention aims to provide a method for removing residual glutaraldehyde in biological materials by indirect centrifugation, which has the following specific technical scheme.
: The method for removing residual glutaraldehyde based on indirect centrifugation comprises the following specific steps:
Step 1: placing the biological material containing glutaraldehyde into glycine solution for neutralization treatment, wherein the neutralization treatment is to place the biological material containing glutaraldehyde into glycine solution, and ultrasonically soak the biological material for 10-30 min at the power of 300-600W, and the ultrasonic soaking temperature is controlled to be 25-40 ℃;
Step 2: putting the biological material subjected to neutralization treatment into filter cloth, adding a small amount of water (preferably pure water) into the filter cloth to keep the biological material moist, sealing the filter cloth, fixing the filter cloth in the middle of a centrifuge tube, centrifuging for 5-30 min in an indirect centrifugation mode with the rotating speed of 4000-10000 rpm, and controlling the temperature of the whole centrifugation process to be 17-40 ℃;
Step 3: the centrifugation operation of step 2 was repeated 1 time.
Further, the neutralization treatment in the step 1 is to put the biological material containing glutaraldehyde into glycine solution and soak the biological material for 30min at 400W power or 10min at 600W power.
It will be appreciated that the present invention uses a short-time ultrasonic soaking to neutralize glutaraldehyde in the biological material.
Further, the molar concentration of the glycine solution in the step 1 is 0.01mol/L to 1mol/L.
Preferably, the molar concentration of the glycine solution is 0.2mol/L.
Further, in the step 2, the centrifugal separation is performed for 30min by an indirect centrifugal method with the rotating speed of 4000 rpm.
Further, the mesh number of the filter cloth in the step 2 is 50-500 mesh.
Further, the amount of water added to the filter cloth in the step 2 is 2 to 5ml.
Further, the biological materials in the filter cloth are taken out for rinsing by pure water after the indirect centrifugal operation is completed in the step 2 and the step 3.
Further, the kind of the biological material includes decellularized matrix, collagen sponge, gelatin, elastin, fibroin, etc. The basic structural units of the materials are amino acids, and free amino or hydroxyl groups on the amino acids can undergo a crosslinking reaction with glutaraldehyde.
It will be appreciated that the method of the present invention for removing residual glutaraldehyde may also be applied to chitin, chitosan, agarose, hyaluronic acid, fibrinogen, chondroitin sulfate, alginate, aminodextran or liposomes.
Further, the biological material containing glutaraldehyde is a biological material which is crosslinked for 10-48 hours at room temperature in glutaraldehyde solution with the mass concentration of 0.001-0.1%.
Further, the biological material containing glutaraldehyde is a biological material which is crosslinked for 24 hours at room temperature in glutaraldehyde solution with the mass concentration of 0.001-0.1%.
Further, the extracellular matrix-removed after the above steps is freeze-dried in a vacuum freeze-dryer to be preserved.
Beneficial technical effects
The invention provides a method for thoroughly removing glutaraldehyde remained in biological materials by mainly adopting an indirect centrifugation method. Specifically, firstly, glycine ultrasound is adopted to soak biological materials containing glutaraldehyde for a short time, glutaraldehyde is neutralized, and then indirect centrifugation is carried out for 2 times, so that residual glutaraldehyde in the biological materials is thoroughly removed. The advantage of this operation is that, firstly, the biological material can be better prevented from yellowing by short-time soaking with glycine, and further the subsequent application of the biological material in clinic is not affected. The neutralization of glutaraldehyde by glycine can be accelerated by ultrasonic mode, so that the neutralization of most glutaraldehyde in the biological material by glycine can be completed in a short time, and the color of the biological material can not become too yellow. Then, the neutralized glutaraldehyde and the residual glycine are thoroughly removed by adopting indirect centrifugation, and simultaneously the biological material is protected from deformation and quality change. After 2-wheel indirect mechanical centrifugation, the biological material can almost change back to the original color without deformation, and simultaneously, the pentadiene is completely removed. The detected biological material has almost no cytotoxicity, and is suitable for clinical popularization and application.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below. Like elements or portions are generally identified by like reference numerals throughout the several figures. In the drawings, elements or portions thereof are not necessarily drawn to scale. It will be apparent to those of ordinary skill in the art that the drawings in the following description are of some embodiments of the invention and that other drawings may be derived from these drawings without inventive faculty.
FIG. 1 is a graph showing the effect of the milky thin film extracellular matrix removal of porcine peritoneum after degreasing and decellularization treatment;
FIG. 2 is a color chart of the extracellular matrix-removed crosslinked with glutaraldehyde after soaking in glycine solution at room temperature for 24 hours;
FIG. 3 is a color chart of the extracellular matrix-free and glycine solution after ultrasound soaking for 30min after crosslinking with glutaraldehyde;
FIG. 4 is a diagram showing the reaction mechanism of glycine and free glutaraldehyde;
FIG. 5 is a High Performance Liquid Chromatography (HPLC) method for detecting glutaraldehyde residue after soaking the decellularized matrix crosslinked with glutaraldehyde in glycine solution at room temperature for 24 hours;
FIG. 6 is a high performance liquid chromatography residual glutaraldehyde chromatogram after ultrasonic soaking of the decellularized matrix crosslinked with glutaraldehyde with glycine solution for 30 min;
FIG. 7 is a color map of extracellular matrix removal after glycine short-term ultrasonic soaking combined with two indirect mechanical centrifuges;
FIG. 8 is a high performance liquid chromatography detection residual chromatogram of extracellular matrix removal after glycine short-time ultrasonic soaking combined with two indirect mechanical centrifugation;
FIG. 9 is a graph of cytotoxicity assays after glutaraldehyde removal by various methods and materials;
FIG. 10 is a graph of residual chromatogram of collagen sponge high performance liquid chromatography detection after glycine short time ultrasonic soaking combined with two indirect mechanical centrifuges.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. It will be apparent that the described embodiments are some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Herein, "and/or" includes any and all combinations of one or more of the associated listed items.
Herein, "plurality" means two or more, i.e., it includes two, three, four, five, etc.
It should be noted that, in this document, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising one … …" does not exclude the presence of other like elements in a process, method, article, or apparatus that comprises the element.
As used in this specification, the term "about" is typically expressed as +/-5% of the value, more typically +/-4% of the value, more typically +/-3% of the value, more typically +/-2% of the value, even more typically +/-1% of the value, and even more typically +/-0.5% of the value.
In this specification, certain embodiments may be disclosed in a format that is within a certain range. It should be appreciated that such a description of "within a certain range" is merely for convenience and brevity and should not be construed as a inflexible limitation on the disclosed ranges. Accordingly, the description of a range should be considered to have specifically disclosed all possible sub-ranges and individual numerical values within that range. For example, a rangeThe description of (c) should be taken as having specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as individual numbers within such ranges, e.g., 1,2,3,4,5, and 6. The above rule applies regardless of the breadth of the range.
Noun interpretation
The short-time ultrasonic soaking refers to the soaking time of the biological material crosslinked with glutaraldehyde in glycine solution with specific concentration of not more than 30min.
The term "indirect centrifugation" used in the present invention means that the material to be centrifuged is not directly placed in a centrifuge tube, but placed in a protective container and then placed in the centrifuge tube for centrifugation.
Example 1
This example provides an example of the preparation of extracellular matrix-free porcine peritoneum as a starting material
(1) Pig peritoneal degreasing: removing most fat attached to the porcine peritoneum tissue manually, washing the porcine peritoneum by using normal saline for 3-8 times, soaking the washed porcine peritoneum in an organic reagent for a certain time at room temperature for degreasing, and washing the degreased porcine peritoneum in pure water for 3-8 times to remove the residual organic reagent in the porcine peritoneum. The organic reagent for pig peritoneal degreasing optionally comprises any one of acetone, isopropanol, diethyl ether, methanol, chloroform, ethyl acetate or n-hexane. The ratio of the pig peritoneum to the organic reagent is 1:6-1:14 (w/v).
(2) Pig peritoneal decellularization treatment: the defatted pig peritoneum is soaked in mixed alkali solution of sodium hydroxide and sodium chloride to further remove cells, the concentration of sodium hydroxide is 0.1% -2% (w/w), the concentration of sodium chloride is 0.5% -2% (w/w), then the pig peritoneum is washed in pure water for 3-8 times until the solution is neutral, and the extracellular matrix is obtained after freeze drying, see figure 1.
It will be appreciated that materials suitable for use in the methods of the present invention may also include collagen sponges, collagen gels, collagen films, and collagen materials derived from other mammals.
Example 2
The extracellular matrix material (abbreviated as material) treated in example 1 was cut into 1.5cm×1.5cm sheets, immersed in glutaraldehyde solution with a mass concentration of 0.001% -0.1%, crosslinked at room temperature for 24 hours, and rinsed 3 times with pure water. The mechanical strength of the obtained acellular matrix crosslinked with glutaraldehyde is obviously enhanced. The decellularized extracellular matrix crosslinked with glutaraldehyde was then used in (1): soaking in 0.2mol/L glycine solution for 24 hours at normal temperature and (2): soaking in 0.2mol/L glycine solution with 400W power for 30min at 25-40 deg.c. The material treated by the methods (1) and (2) was rinsed 3 times with pure water to remove most of the surface unreacted glycine solution. The treated extracellular matrix was freeze-dried in a vacuum freeze-dryer for preservation.
FIG. 2 shows the extracellular matrix after 24 hours of immersion in glycine solution after crosslinking treatment with glutaraldehyde, which is dark yellow. FIG. 3 shows the extracellular matrix after ultrasonic soaking in glycine solution for 30min after crosslinking treatment with glutaraldehyde, which is pale yellow. The reason for the yellowing of the color is that glycyl glutaraldehyde formed by the reaction of free glutaraldehyde with glycine appears yellow, the longer the time of immersion in glycine solution, the darker the yellow color that appears. FIG. 4 is a graph showing the reaction mechanism of glycine and free glutaraldehyde, and the extracellular matrix-removed soaking solution shows yellow color after glycine soaking.
Adding the extracellular matrix removed by the steps (1) and (2) into physiological saline according to the proportion of 6cm 2/mL, and carrying out constant-temperature oscillation leaching (24+/-2) at the temperature of (37+/-1) ℃ for 24+/-2 hours, wherein the oscillation speed is 200rpm. After the leaching, the sample is separated from the liquid, cooled to room temperature, and the liquid is taken as leaching liquid. Glutaraldehyde residue tests were performed with reference to DB 13/T5127.11-2019 (determination of toxic and harmful substances in polymeric material extract of implantable medical device part 11: glutaraldehyde migration high performance liquid chromatography) extract. The glutaraldehyde content of the extracellular matrix removed after 24h of soaking in the glycine solution (1) is 0.103mg/L, as shown in figure 5; the glutaraldehyde content of the extracellular matrix removed after 30min of ultrasonic soaking in the glycine solution (2) was 1.748mg/L, as shown in FIG. 6.
Cytotoxicity test: sterilizing the extracellular matrix obtained by the steps of (1) and (2) under an ultraviolet lamp for more than 8 hours. Then, MEM medium containing fetal bovine serum was added in a ratio of 6cm 2/mL, and the mixture was subjected to constant temperature shaking leaching (24.+ -.2) at a shaking speed of 200rpm at a temperature of (37.+ -.1) DEG C for a period of 24.+ -. 2 hours. After the leaching, the sample is separated from the liquid, cooled to room temperature, and the liquid is taken as leaching liquid. The in vitro cytotoxicity test was performed with reference to GB/T16886.5-2017 (medical device biological evaluation part 5: in vitro cytotoxicity test) leach liquor, and the cytotoxicity test method was referred to CCK-8 method. Wherein, the cell survival rate obtained by the test is more than or equal to 70 percent and is qualified, and the cell survival rate obtained by the test is less than 70 percent and is unqualified. The results are shown in FIG. 9. (1) (2) cytotoxicity of materials see example 2 (1) of FIG. 9 and example 2 (2) of FIG. 9, respectively. It can be seen that after short-time ultrasonic soaking with glycine solution, the residual glutaraldehyde content in the acellular matrix is higher, so that the cytotoxicity is higher and the cell activity is lower.
Example 3
The decellularized extracellular matrix crosslinked with glutaraldehyde in example 2 was further subjected to indirect mechanical centrifugation after ultrasonic soaking in 0.2mol/L glycine solution at 400W for 30 min. Putting the extracellular matrix in 500-mesh filter cloth, further adding 5ml of purified water into the filter cloth, sealing the filter cloth, fixing the filter cloth in the middle of a centrifuge tube, controlling the centrifugation temperature to be 17-40 ℃ (controlling the temperature centrifugation to be critical for protecting biological materials), setting the centrifugation rotating speed to be 4000-10000 rpm, and centrifuging for 5-30 min, and centrifuging twice. The material after indirect mechanical centrifugation appears lighter yellow, approaching the color of the decellularized matrix material itself, see fig. 7, illustrating further removal of glutaraldehyde neutralized by glycine. The material was continuously added to physiological saline at a rate of 6cm 2/mL, and subjected to constant temperature shaking leaching (24.+ -. 2) at (37.+ -. 1) ℃ C. For an hour at a shaking speed of 200rpm. After the leaching, the sample is separated from the liquid, cooled to room temperature, and the liquid is taken as leaching liquid. Glutaraldehyde residue tests were performed with reference to DB 13/T5127.11-2019 (determination of toxic and harmful substances in polymeric material extract of implantable medical device part 11: glutaraldehyde migration high performance liquid chromatography) extract. The residual glutaraldehyde content in the extracellular matrix of the present embodiment was not detected, and the instrument detection limit was 0.025mg/L, as shown in FIG. 8, indicating that the residual glutaraldehyde was effectively removed by indirect mechanical centrifugation. The cytotoxicity of the material is shown in fig. 9, and the cell viability is significantly higher than that of the extracellular matrix-removed material immersed in glycine solution for 24 hours in example 2 (1).
Example 4
This example provides glutaraldehyde removal results for glutaraldehyde-crosslinked collagen sponges
The collagen sponge was treated according to the glycine short time ultrasonic soak of example 2 and the mechanical centrifugation method of example 3. After centrifugation was completed, most of the surface unreacted glycine solution was removed by rinsing with pure water 3 times. And freeze-drying the treated collagen sponge in a vacuum freeze dryer so as to facilitate preservation. High performance liquid chromatography and cytotoxicity tests were then performed according to the standard methods of the above examples. As a result, no residual glutaraldehyde was detected, and the limit of detection by the instrument was 0.025mg/L, as shown in FIGS. 9 and 10.
Example 5
This example provides residual glutaraldehyde levels in decellularized matrix under various ultrasonic soaking and centrifugation procedures
TABLE 1 glutaraldehyde residues for different ultrasonic soaking operations
| Ultrasonic power | Ultrasonic time | Glutaraldehyde residue |
| 300W | 30min | 2.146mg/L |
| 400W | 30min | 1.748mg/L |
| 600W | 10min | 1.836mg/L |
From the above experiments it can be seen that the residual glutaraldehyde content was minimal after 30min of ultrasound at 400W, so that the material at this ultrasound parameter was selected to continue with indirect mechanical centrifugation.
TABLE 2 glutaraldehyde residues at different centrifugation times
| Number of centrifugation times | Centrifugal parameters | Glutaraldehyde residue |
| 1 Time | 4000rpm/30min | 0.153mg/L |
| 2 Times | 4000rpm/30min | ≤0.025mg/L |
From the above experiments, it can be seen that there is little glutaraldehyde residue after centrifugation 2 nd time, so the method of the present invention is finally confirmed to be performed 2 times of mechanical centrifugation.
TABLE 3 glutaraldehyde residues for different centrifugation parameters
From the above experiments, it can be seen that the residual glutaraldehyde amount was minimized after centrifugation at 4000rpm for 30min, and thus the centrifugation parameters were selected as optimal operation.
The embodiments of the present invention have been described above with reference to the accompanying drawings, but the present invention is not limited to the above-described embodiments, which are merely illustrative and not restrictive, and many forms may be made by those having ordinary skill in the art without departing from the spirit of the present invention and the scope of the claims, which are to be protected by the present invention.
Claims (10)
1. The method for removing residual glutaraldehyde based on indirect centrifugation is characterized by comprising the following specific steps:
Step 1: placing the biological material containing glutaraldehyde into glycine solution for neutralization treatment, wherein the neutralization treatment is to place the biological material containing glutaraldehyde into glycine solution, and ultrasonically soak the biological material for 10-30 min at the power of 300-600W, and the ultrasonic soaking temperature is controlled to be 25-40 ℃;
step 2: putting the biological material subjected to neutralization treatment into filter cloth, adding a small amount of water into the filter cloth to keep the biological material moist, sealing the filter cloth, fixing the filter cloth in the middle of a centrifuge tube, centrifuging for 5-30 min in an indirect centrifugation mode with the rotating speed of 4000-10000 rpm, and controlling the temperature of the whole centrifugation process to be 17-40 ℃;
Step 3: the centrifugation operation of step 2 was repeated 1 time.
2. The method according to claim 1, wherein the neutralization treatment in step 1 is to put the glutaraldehyde-containing biological material in glycine solution and to ultrasonically soak for 30 minutes at 400W or for 10 minutes at 600W.
3. The method according to claim 1, wherein the glycine solution in the step 1 has a molar concentration of 0.01 to 1mol/L.
4. A process according to claim 3, wherein the glycine solution has a molar concentration of 0.2mol/L.
5. The method according to claim 1, wherein the step 2 is performed by indirect centrifugation at 4000rpm for 30min.
6. The method according to claim 1, wherein the mesh number of the filter cloth in the step 2 is 50 to 500 mesh.
7. The method according to claim 1, wherein the amount of water added to the filter cloth in step 2 is 2 to 5ml.
8. The method according to claim 1, wherein the biological material in the filter cloth is taken out for rinsing with pure water after the completion of the indirect centrifugation operation in the steps 2 and 3.
9. The method of claim 1, wherein the class of biological material comprises decellularized extracellular matrix, collagen sponge, gelatin, elastin, or fibroin.
10. The method according to claim 1, wherein the glutaraldehyde-containing biomaterial is a biomaterial crosslinked at room temperature for 10 to 48 hours in a glutaraldehyde solution having a mass concentration of 0.001 to 0.1%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410405439.6A CN118059315A (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde based on indirect centrifugation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311244739.2A CN117045865B (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde in glutaraldehyde-crosslinked biological material |
| CN202410405439.6A CN118059315A (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde based on indirect centrifugation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311244739.2A Division CN117045865B (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde in glutaraldehyde-crosslinked biological material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118059315A true CN118059315A (en) | 2024-05-24 |
Family
ID=88653794
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311244739.2A Active CN117045865B (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde in glutaraldehyde-crosslinked biological material |
| CN202410405439.6A Pending CN118059315A (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde based on indirect centrifugation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311244739.2A Active CN117045865B (en) | 2023-09-25 | 2023-09-25 | Method for removing residual glutaraldehyde in glutaraldehyde-crosslinked biological material |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN117045865B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US6214055B1 (en) * | 1998-10-30 | 2001-04-10 | Mures Cardiovascular Research, Inc. | Method and kit for rapid preparation of autologous tissue medical devices |
| JP2004018685A (en) * | 2002-06-17 | 2004-01-22 | Unitika Ltd | Method for producing crosslinked gel with reduced discoloration and dried product of gel |
| US20180250437A1 (en) * | 2015-08-27 | 2018-09-06 | Hans U. BAER | Method for preparing a three-dimensional polymer scaffold for tissue engineering |
| US20180251505A1 (en) * | 2016-11-17 | 2018-09-06 | University Of South Carolina | Keratin-based hydrogels |
| CN110694112A (en) * | 2019-09-12 | 2020-01-17 | 厉忠逵 | Multi-connection anti-calcification treatment method for heterogeneous biological tissue material |
| CN115006596A (en) * | 2022-07-21 | 2022-09-06 | 成都奇璞生物科技有限公司 | Process for treating biological tissue sheet and biological tissue sheet obtained by the treatment process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089145B1 (en) * | 1982-03-08 | 1987-06-16 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US12083009B2 (en) * | 2020-04-15 | 2024-09-10 | Vitae LLC | Method of processing collagen-based tissue for bioprosthetic devices |
| CN113786515B (en) * | 2021-08-17 | 2022-10-11 | 中南大学湘雅二医院 | Method for treating cross-linked biological tissue |
-
2023
- 2023-09-25 CN CN202311244739.2A patent/CN117045865B/en active Active
- 2023-09-25 CN CN202410405439.6A patent/CN118059315A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US6214055B1 (en) * | 1998-10-30 | 2001-04-10 | Mures Cardiovascular Research, Inc. | Method and kit for rapid preparation of autologous tissue medical devices |
| JP2004018685A (en) * | 2002-06-17 | 2004-01-22 | Unitika Ltd | Method for producing crosslinked gel with reduced discoloration and dried product of gel |
| US20180250437A1 (en) * | 2015-08-27 | 2018-09-06 | Hans U. BAER | Method for preparing a three-dimensional polymer scaffold for tissue engineering |
| US20180251505A1 (en) * | 2016-11-17 | 2018-09-06 | University Of South Carolina | Keratin-based hydrogels |
| CN110694112A (en) * | 2019-09-12 | 2020-01-17 | 厉忠逵 | Multi-connection anti-calcification treatment method for heterogeneous biological tissue material |
| CN115006596A (en) * | 2022-07-21 | 2022-09-06 | 成都奇璞生物科技有限公司 | Process for treating biological tissue sheet and biological tissue sheet obtained by the treatment process |
Non-Patent Citations (1)
| Title |
|---|
| 沈培康等: "《电化学氧还原的理论基础和应用技术》", 31 December 2018, 广西科学技术出版社, pages: 147 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117045865A (en) | 2023-11-14 |
| CN117045865B (en) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002309898B2 (en) | EB matrix production from fetal tissues and its use for tissue repair | |
| US5028695A (en) | Process for the manufacture of collagen membranes used for hemostasis, the dressing of wounds and for implants | |
| US4389487A (en) | Process for the preparation of a collagen product for medical and cosmetic purposes | |
| EP1968659B1 (en) | Biological surgical patch and method of making | |
| AU2002309898A1 (en) | EB matrix production from fetal tissues and its use for tissue repair | |
| AU2013289661B2 (en) | Decellularization method for preparing extracellular matrix support material | |
| KR101410533B1 (en) | A method for treating material derived from biological tissue | |
| IE20050018A1 (en) | Tissue graft scaffold | |
| IE84394B1 (en) | Tissue graft scaffold | |
| CN107233622B (en) | Preparation method of acellular tissue membrane | |
| AU2021407693A1 (en) | Biological prosthetic tissue processing method, and biological prosthetic heart valve | |
| CN117045865B (en) | Method for removing residual glutaraldehyde in glutaraldehyde-crosslinked biological material | |
| CN112755247A (en) | Acellular dermal matrix and preparation method thereof | |
| KR102451565B1 (en) | Prehydrated-type acellular skin substitute and method of making the same | |
| RU2691983C1 (en) | Method for purification, modification and sterilization of bone tissue and skin matrix derivatives using supercritical fluid | |
| CN116640356A (en) | Preparation method of enhanced bovine collagen sponge | |
| CH627078A5 (en) | Process for the preparation of a sterile collagen product with felt-like or web-like fibre structure | |
| CN114848912B (en) | Acellular dermis and preparation method thereof | |
| RU2810102C1 (en) | Method of obtaining xenogenic biomaterial from reindeer aorta | |
| CN117867852A (en) | Pretreatment method in collagen fiber preparation process and preparation method thereof | |
| JP5726593B2 (en) | Method for producing non-brominated collagen and non-brominated collagen obtained thereby | |
| CA2448436C (en) | Eb matrix production from fetal tissues and its use for tissue repair | |
| RU2166252C2 (en) | Method for removing bone marrow from spongious bone grafts | |
| CN117258046A (en) | Decalcified bone for repairing bone defect, preparation method and application thereof | |
| CN112957533A (en) | Preparation method of imitation cortical bone repair material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |